LLY
A fresh stamp of approval
Pursue Wealth Partners LLC just filed for a new stake in Eli Lilly, buying 2,136 shares worth about $2.3 million. That’s not exactly pocket change, even for a fund that’s juggling a bigger portfolio.
Why this matters
On its own, one new position doesn’t move a mega-cap like Lilly the way a blockbuster drug headline would. But it does add to the chorus of investors saying, “Yes, this is still the name to own,” especially after Lilly posted a Q4 beat and rolled out FY2026 guidance.
The Lilly machine keeps humming
The article also reminds you that Lilly’s Q4 wasn’t just a win on the bottom line. Earnings came in at $7.54 per share versus $7.48 expected, and revenue hit $19.29 billion versus $17.85 billion expected. Then there’s the guidance: FY2026 EPS of $33.50 to $35.00, which keeps the company in rarefied air.
Big picture
This isn’t a “blink and you miss it” catalyst, but it is another breadcrumb showing institutional buyers still want exposure to Lilly’s growth story. When the stock already has a crowded fan club, every new filing is basically another person showing up to the party with a folding chair.